Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data

 
• By Joseph Haas

Two weeks after obtaining its third cancer indication and the same day Kite CEO Christi Shaw’s departure was announced, Gilead’s antibody-drug conjugate yielded Phase II data it says will help toward full approval in urothelial cancer.

Antibody-drug conjugate
Gilead continues working toward adding to ADC Trodelvy's label • Source: Shutterstock

More from Clinical Trials

More from R&D